
‘Out of the box' pill could eliminate life-threatening allergic reactions for millions of people
The breakthrough could lead to new protection for millions, say scientists.
2
Zileuton, an oral pill used to treat asthma, worked "shockingly well" in blocking allergic reactions to food in mice in new research.
Researchers found the mice went from being 95 per cent susceptible to anaphylaxis to 95 per cent protected.
Now a clinical trial has been launched to test the same approach in humans.
Zileuton, recently approved in the United States and available on prescription in the UK, was found to "nearly eliminate" life-threatening allergic reactions to food allergens in mice.
The discovery came after scientists identified, in mice, a previously unknown role for a gene called DPEP1, which they found is "essential" in regulating anaphylaxis - a rapid and potentially deadly allergic reaction.
By using it to block the pathway involving this gene, the team at at Northwestern University in Illinois nearly eliminated allergic responses in mice that were previously highly susceptible to food-induced anaphylaxis.
The mice were given peanut extract orally shortly after receiving Zileuton while the team monitored for symptoms.
Study co-senior author Dr. Stephanie Eisenbarth, of Northwestern University Feinberg School of Medicine, said: "It was actually shocking how well Zileuton worked."
The discovery of the new pathway came after a years-long forward genetic screen, a process where researchers breed generations of mice to narrow down the specific genes responsible for biological differences, such as susceptibility to food allergy.
Once the team found the DPEP1 gene controlled leukotrienes in the gut - inflammatory molecules already targeted by asthma drugs - they tested Zileuton, which blocks their production.
Allergist explains the difference between allergies and anaphylaxis
Food allergies are on the rise, affecting around one in 10 people.
But scientists say predicting an allergic person's risk of anaphylaxis and preventing severe reactions from accidental exposure remains a challenge.
Currently, there are only two approved treatments for certain food allergies - and no cure.
One is an oral immunotherapy for peanut allergy, which doesn't work for all patients and can itself trigger anaphylaxis.
The other, omalizumab, is an expensive jab that also isn't effective for all allergy patients.
But the research team say Zileuton is a simple pill that temporarily shields allergy patients by blocking the body's anaphylactic pathway before it activates.
2
Prof Williams said: "This is a totally different, out-of-the-box approach to treat food allergy, unlike anything we've tried before.
"We've seen tragic, even fatal reactions from hidden ingredients like ground peanuts in a sauce.
"For parents sending their child to a birthday party, or for anyone flying where they can't control what's being served, this could be a powerful protective drug."
The Northwestern team launched a small clinical trial in July to test whether blocking the newly identified pathway with Zileuton in humans is as effective as it was in mice.
Their findings, published in the journal Science, also shed light on the long-standing puzzle of why some people test positive for food allergens but experience no symptoms when they eat the food.
Dr Eisenbarth said: "Let's say you're told you're allergic to peanuts based on a blood test, but you've eaten peanuts your whole life without any problems.
"This pathway we discovered may be one explanation for why some of those people are protected."
She says that group has been a "challenge" for doctors and a source of stress for patients because current diagnostic tests only estimate allergy risk, not tolerance.
Dr Eisenbarth said: "Our findings open a whole new area for future research into how people develop food allergies in the first place, and why some react while others don't."
She added: "If you'd asked me five or six years ago to guess the pathway that would lead to this discovery, I never would have picked this gene or the leukotriene molecules."
Symptoms of anaphylaxis - and what to do if you have it
The symptoms of anaphylaxis can happen very quickly. They usually start within minutes of coming into contact with something you're allergic to, such as a food, medicine or insect bite.
You should call 999 if:
Your lips, mouth, throat or tongue suddenly become swollen
You're breathing very fast or struggling to breathe (you may become very wheezy or feel like you're choking or gasping for air)
Your throat feels tight or you're struggling to swallow
Your skin, tongue or lips turn blue, grey or pale (if you have black or brown skin, this may be easier to see on the palms of your hands or soles of your feet)
You suddenly become very confused, drowsy or dizzy
Someone faints and cannot be woken up
A child is limp, floppy or not responding like they normally do (their head may fall to the side, backwards or forwards, or they may find it difficult to lift their head or focus on your face)
What to do if you have anaphylaxis
Follow these steps if you think you or someone you're with is having an anaphylactic reaction...
Use an adrenaline auto-injector (such as an EpiPen) if you have one – instructions are included on the side of the injector.
Call 999 for an ambulance and say that you think you're having an anaphylactic reaction.
Lie down – you can raise your legs, and if you're struggling to breathe, raise your shoulders or sit up slowly (if you're pregnant, lie on your left side).
If you have been stung by an insect, try to remove the sting if it's still in the skin.
If your symptoms have not improved after 5 minutes, use a 2nd adrenaline auto-injector.
Do not stand or walk at any time, even if you feel better.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
29 minutes ago
- BBC News
Butterfly from Southern Europe spotted in UK for first time
A species of butterfly previously only found in Southern Europe has been seen in the UK for the first time, according to charity Butterfly have tracked the Southern Small White butterfly's rapid expansion northwards through Europe over recent first UK sighting was confirmed at Landguard Bird Observatory in Suffolk, after a volunteer managed to snap a is not yet clear what has driven the species' expansion, though a warming climate is thought to be part of the answer. Until recently, the range of the Southern Small White was limited to Southern Europe, in particular south-east Conservation says the species was first spotted north of the Alps in France and Germany in 2008, and since then it has gradually extended its range, reaching the Netherlands in 2015 and Calais in first UK visitor was a female butterfly and was spotted at Landguard Nature Reserve on 2 August by volunteer Will Brame, according to BirdGuides. Its identification as a Southern Small White was confirmed by butterfly expert Chris van Swaay of Dutch Butterfly Corton, a County Recorder for Butterflies in Suffolk, contacted us about the story through Your Voice, Your BBC it is thought a warming climate has played a role in its spread, modelling from a 2008 Climatic Risk Atlas of European Butterflies showed that even under the most extreme warming scenarios the species was not expected in the Low Countries until after 2050. Dr Dan Hoare, Director of Nature Recovery at Butterfly Conservation, said the species had made an "ecological leap"."There are species that are rare in the UK and periodically over the years they have turned up in ones and twos... but it's not really indicating any significant shift in our fauna," he said."Southern Small White is very different. It's basically colonised northern Europe from the Swiss Alps to the North Sea in the last decade, moving north at a rate of about 100 kilometres [62 miles] a year."But whether the species stays long term is yet to be seen, he says, as its food source is a garden species called Candytuft that is not as widely planted species has never been a migrant to the UK, and is yet to have been recorded breeding here, which is what a resident species would do.


The Independent
2 hours ago
- The Independent
Near 50% rise in people contacting NSPCC over children's welfare in sports settings, charity says
The number of people contacting a helpline with concerns about the welfare of young people in sports clubs rose by almost 50 per cent in a year, a children 's charity has said. The NSPCC said the rise might have been prompted by greater awareness following high-profile investigations into sports settings in recent years, as well as increased knowledge about the helpline. It said said the jump also 'possibly shows a rise in the abuse of children in sports settings', but noted that adult survivors have also been reporting historic abuse to the helpline. The NSPCC Helpline had 623 contacts from adults across the UK with concerns about a child's welfare in a sports setting in the 12 months to the end of March. This was up from 425 the previous year – a rise of 47 per cent. The most common concerns raised by contacts to the helpline were about sexual abuse or exploitation, emotional abuse and physical abuse. Christian McMullan, NSPCC professional learning services director, said it is 'vital that parents, carers, staff and volunteers not only know how to spot the signs that a child may be experiencing difficulties, but also what to do and who to speak to, so that a child can be supported'. He added: 'Our Keeping Your Child Safe in Sport resources are free, easy to access and use, and can help adults understand more about what role they can play in ensuring young people can enjoy their sport in safety.'


The Independent
2 hours ago
- The Independent
Cancer patients to receive ‘game-changing' vaccine in new NHS trial
Patients in England with head and neck cancer will be fast-tracked onto a clinical trial for a "potentially transformative" new vaccine, under an initiative announced by the NHS. The first patients have received the jab, which uses mRNA technology to train the immune system to fight cancerous cells, with more set to be enrolled at their nearest NHS hospital. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. Aggressive forms are difficult to treat, with high rates of recurrence and two-year survival rates under 50 per cent. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of human papillomavirus (HPV). These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. More than 100 patients with advanced forms of the disease will be matched to the trial, known as AHEAD-MERIT (BNT113), which will run at 15 hospitals over the next year. Health minister Karin Smyth described the plan as a 'massive win for cancer patients'. 'These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.' NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK -funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: 'It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.' Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial 'offers crucial hope to those living with advanced stages of cancer'. 'While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones,' she added. Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: 'As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. 'With this aggressive cancer, you live in the fear of reoccurrence every day – so anything that could help control the disease or give people peace of mind is groundbreaking – it'll allow people to get on with their lives and move forward.' The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: 'The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. 'Research into personalised cancer treatments is vital. There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. 'That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer.'